Facts & Figures

554
Organizations
37595
Employees
12.2 bn
Sales / Year
4602
Publications
Source: Vienna Life Science Report 2017/18 (Data: 2017) More Information

Are you up to date?

News

Ottobock creates considerable value

Growth for technology leader in “Wearable Human Bionics”*. Management Board reports 2018 financials and outlines...

MedUni Vienna: Mitral regurgitation: more precise classification of severity now possible

For years now, cardiology experts have been arguing about how to determine the degree of severity in patients with...

Sanochemia: Operatives Geschäft beginnt sich zu stabilisieren

Die börsennotierte Sanochemia AG (ISIN AT0000776307, ISIN DE000A1G7JQ9) gibt heute die Zahlen für das erste Halbjahr des...

All news

Driven by curiosity, inspired by our city...

Twitter @lifesciencevie

Events

28.5. - 29.5.2019
International meeting

Vienna

dHealth 2019

13th Annual Conference on Health Informatics meets Digital Health "From eHealth to dHealth"

LISAvienna event

Vienna

BI Office Hours in Vienna

In collaboration with LISAvienna, Boehringer Ingelheim invites the regional biomedical community to join personalized...

3.6. - 6.6.2019
International meeting

Philadelphia

BIO International Convention

It starts with one... Advances in biotech begin with one meeting, one theory, one trial, one breakthrough. You make it...

Wien

MedUni Wien: Eröffnung des Klinischen Labors für Bionische Extremitätenrekonstruktion

Innovative rekonstruktive Ansätze zu Wiederherstellungsmöglichkeiten an der Grenze zwischen Mensch und Maschine

All events

Why Vienna?

Philipp von Lattorff - Boehringer Ingelheim
(C) Boehringer Ingelheim / Marion Carniel

Political stability is a major factor when considering major investments in a country. Austria scores very highly in that regard, as it does in terms of infrastructure and standard of living. Without a doubt, however, one of the most important considerations for a research-driven company is research subsidies. This also played a decisive role in the decision to invest 700 million euros in the construction of our new biopharmaceutical production facility in Vienna. We are looking for highly qualified candidates to fill the 500 new positions, created for this project, and attach great importance for that reason to the training and qualifications of potential employees.

Philipp von Lattorff
Managing Director at Boehringer Ingelheim RCV GmbH & Co KG